We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » GSK Nabs FDA Approval for First Drug for Treatment of Myelofibrosis
GSK Nabs FDA Approval for First Drug for Treatment of Myelofibrosis
GSK’s Ojjaara (momelotinib), the first and only treatment for myelofibrosis patients with anemia regardless of prior myelofibrosis therapy, received FDA approval on Friday.
